ACE2 and COVID-19: Thus, combined our findings on dACE2 and ACE2 support the recently reported hypothesis that the 3-fold higher ACE2 levels shown in a transcriptome analysis of nasopharyngeal COVID-19 patient samples, compared to the control group [6], are due to dACE2 and not ACE2 [4].